# MOTS-c

> A 16-amino-acid peptide encoded in mitochondrial DNA. Its metabolic and lifespan data come from mice; no human trial of it has reported results.

Source page: https://peptioresearch.com/peptides/mots-c/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-10

## At a glance

- Research status: Preclinical only
- Also known as: MOTs-c, MOTs-C, MOTSc, MOTS-C, Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c
- Identifiers: CAS 1627580-64-6; PubChem CID 146675088; UniProt A0A0C5B5G6
- Molecular weight: 2174.6
- Sequence: MRWQEMGYIFYPRKLR

## What the research shows

Each claim is labelled with the strongest kind of study that supports it, which way the evidence points, and how confident that reading is.

### Pooled observational studies of 602 people found plasma MOTS-c lower in diabetes but higher in obesity, measurements that mass spectrometry has not confirmed.

- Evidence: Human observational. Contradictory. Very low confidence.
- Sources: [1][2][3]

Zhou and colleagues (2024) pooled 6 case-control studies and 1 cross-sectional study, 602 participants in all. Pooling diabetes and obesity together gave lower plasma MOTS-c (SMD = -0.37). In type 2 diabetes alone it was lower (SMD = -0.89); in obesity (BMI above 28) it was higher (SMD = 0.51), a result that was significant only after overweight participants (BMI 24 to 28) were excluded. These are levels of the peptide the body makes, not effects of taking it.

Caveats:
- Associations only. Nothing was administered.
- The ELISA levels these studies rely on could not be confirmed by mass spectrometry, and a 2024 correction by other authors, to their own paper that had cited it, states endogenous MOTS-c "still remains undetected" by that method.
- Only the abstract of the meta-analysis was read.

### In two small human studies, higher plasma MOTS-c went with worse metabolic markers: insulin resistance in 10 lean adults, and metabolic syndrome and liver fat in 125 Chinese participants.

- Evidence: Human observational. Contradictory. Very low confidence.
- Sources: [4][5][2]

Cataldo and colleagues (2018) compared 10 lean and 10 obese adults and found similar levels in both groups (p=0.60). MOTS-c correlated with HOMA, a measure of insulin resistance (r=0.53), and inversely with the Matsuda index of insulin sensitivity (r=-0.46), only in the lean group. Sequeira and colleagues (2021) found MOTS-c "elevated in those with MS", metabolic syndrome, and positively associated with liver fat, in 125 Chinese and 34 European participants.

Caveats:
- Higher levels going with worse markers is the opposite of how MOTS-c is marketed.
- Same assay doubt as every blood-level study on this page.
- Abstracts only.

### In healthy men, circulating MOTS-c was lower with age, while muscle MOTS-c was about 1.5-fold higher in middle-aged and older men than in young men.

- Evidence: Human observational. Mixed. Very low confidence.
- Sources: [6][2]

D'Souza and colleagues (2020) compared young (18 to 30), middle-aged (45 to 55) and older (70 to 81) men. Plasma and muscle moved in opposite directions with age.

Caveats:
- Total sample size is not given in the abstract, which is all that was read.
- Cross-sectional: it cannot show that a change in MOTS-c causes ageing or follows from it.
- Same assay doubt as every blood-level study on this page.

### In 40 patients undergoing coronary angiography, plasma MOTS-c was lower in those with endothelial dysfunction.

- Evidence: Human observational. Supportive. Very low confidence.
- Sources: [7][2]

Qin and colleagues (2018) report MOTS-c "lower in patients with ED compared with patients with normal endothelial function (p=0.007)", endothelial dysfunction being impaired function of the blood vessel lining.

Caveats:
- One small association study. Only the abstract was read.
- Same assay doubt as every blood-level study on this page.

### In three Japanese cohorts totalling 27,527 people, men carrying a variant in the MOTS-c gene (m.1382A>C, K14Q) had a higher prevalence of type 2 diabetes; women did not.

- Evidence: Human observational. Supportive. Low confidence.
- Sources: [8]

Zempo and colleagues (2021) meta-analysed the J-MICC, MEC and TMM cohorts and found that "males but not females with the C-allele exhibit a higher prevalence of T2D". This is a genetic association, not a treatment result.

Caveats:
- No odds ratio is given in the abstract, which is all that was read.
- Claims online that a MOTS-c variant explains Japanese longevity rest on a hypothesis paper that measured nothing.

### Exercise may raise the body's own MOTS-c: in 10 sedentary young men, a single bout raised it in muscle and plasma, while a randomised exercise study found only a non-significant trend.

- Evidence: Human observational. Mixed. Very low confidence.
- Sources: [9][10]

Reynolds and colleagues (2021) report muscle MOTS-c rising 11.9-fold after exercise and plasma 1.6-fold during and 1.5-fold after, with no control group. Muscle levels "remained elevated after a 4-h rest, albeit exhibiting a trend to return to baseline". Von Walden and colleagues (2021), 10 per group, report MOTS-c "showed a trend to increase" and that levels were "not correlated to fitness outcomes".

Caveats:
- This is exercise changing MOTS-c, the reverse of the claim that taking MOTS-c reproduces exercise.
- The 10-person arm is a small part of a mostly mouse paper whose senior authors declare CohBar interests.

### In male mice, MOTS-c injections improved insulin sensitivity and prevented diet-induced obesity, in the discovery paper from the originating group.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [11]

Lee and colleagues (2015) report a roughly 30% higher glucose infusion rate on clamp testing, a measure of insulin sensitivity, in male mice; the paper used outbred CD-1 and C57BL/6 males. Treatment had "no effect on body weight" on a normal diet but "prevented obesity" in mice fed a high-fat diet for 8 weeks (N=10), and restored insulin sensitivity in 12-month-old mice to levels "comparable to young animals".

Caveats:
- Senior authors declare CohBar consultancy and shareholding; CohBar later developed a MOTS-c analogue.
- Group sizes for most experiments were not stated in the text read.
- The authors propose AMPK activation as the mechanism; this is their model, not a human finding.

### In male C57BL/6N mice treated from late life, the originating group reported better physical performance and a lifespan trend that was not statistically significant (P = 0.23).

- Evidence: Animal research. Mixed. Very low confidence.
- Sources: [10]

Reynolds and colleagues (2021) started treatment at 23.5 months. Grip strength and walking tests improved (grip n = 11). For lifespan they report "a trend towards increased median (6.4%) and maximum (7.0%) lifespan"; the overall survival curve gave P = 0.23. A hazard ratio of 0.654 with P = 0.05 applies only up to 31.8 months, a truncated curve. The authors write that "Larger cohorts will be needed".

Caveats:
- No study with a statistically significant lifespan extension was found, in any species.
- Senior authors declare CohBar consultancy and shareholding.
- Male mice of one strain only.

### A group independent of the originating laboratory reports that MOTS-c prevented obesity, insulin resistance and bone loss in ovariectomised mice.

- Evidence: Animal research. Supportive. Low confidence.
- Sources: [12][13]

A group at Air Force Medical University, Xi'an, reports that MOTS-c "prevented ovariectomy-induced obesity and insulin resistance" (Lu 2019) and "significantly alleviated bone loss" on micro-CT (Ming 2016) in ovariectomised C57BL mice, a model of post-menopausal changes.

Caveats:
- Both ovariectomy papers come from one group. Durations and group sizes are not in the abstracts, which are all that was read.
- No human bone study of MOTS-c was found.

### In other mouse models, MOTS-c reduced hyperglycaemia in NOD mice with autoimmune diabetes and reduced weight in male, but not female, high-fat-fed mice.

- Evidence: Animal research. Mixed. Very low confidence.
- Sources: [14][8]

Kong and colleagues (2021) report MOTS-c "ameliorated the development of hyperglycemia" in NOD mice. Zempo and colleagues (2021), in a paper that is mainly a human cohort meta-analysis, report reduced weight and better glucose tolerance in high-fat-fed male mice; female mice were unaffected, and the K14Q variant peptide did not have the effect.

Caveats:
- Both include an author from the originating group. Kong and colleagues declare no competing interests. Abstracts only; group sizes and durations not stated.

### A mass spectrometry method could not confirm the ELISA-measured levels of MOTS-c in human plasma, so the blood-level studies may not be measuring what they report.

- Evidence: In-vitro. Contradictory. Low confidence.
- Sources: [2][3]

Knoop and colleagues (2019) built a mass spectrometry method for doping control with a detection limit of 100 pg/mL. ELISA levels of 45.9 to 218.5 ng/mL in 20 healthy people "could not be confirmed". In a 2024 correction to their own 2021 paper, which had cited this work as mass spectrometry proof, Emser and colleagues write that the test "failed to detect the circulating cell-free form of MOTS-c" while detecting the synthetic control, and that endogenous MOTS-c "still remains undetected" by this technique.

Caveats:
- ELISA results also disagree with each other: about 0.5 ng/mL in one study, 45.9 to 218.5 ng/mL in this one.
- No later mass spectrometry detection was found, though the search was not exhaustive.

## Reported and theoretical risks

### Immunogenicity and impurities in compounded products

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [15]

FDA states that compounded drugs containing MOTs-C "may pose significant risk for immunogenicity" for certain routes of administration, and "may have complexities with regard to peptide-related impurities and API characterization."

### No human safety data

- Evidence: Mechanistic reasoning. Severity: unknown.
- Sources: [15]

FDA "has not identified any human exposure data on drug products containing MOTs-C" and "lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans." No case report or adverse event series was found in the research behind this page.

## Regulatory status

- US, FDA: unclear (as of 2026-04-22). FDA lists MOTs-C in the table of bulk drug substances nominated for compounding but withdrawn: "Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans." [15]
- US, FDA: unclear (as of 2026-08-06). MOTs-c (free base) and MOTs-c acetate were on the agenda of FDA's Pharmacy Compounding Advisory Committee on 23 July 2026, with the uses evaluated stated as "Obesity and osteoporosis". No vote or outcome was found on the meeting page, reopened on 6 November 2026. [16]
- US, FDA advisory committee: unclear (as of 2026-11-06). Second hand: a trade journal reports that on 23 July 2026 the committee voted 7 to 5, with two abstentions, to recommend adding MOTS-c to the 503A bulks list, against FDA's own proposal; a law firm also reports a vote in favour, without a count. Neither report says whether the vote covers the free base, the acetate or both. FDA's meeting page, reopened on 6 November 2026, posts no vote record, though HHS's October 2026 policy states that the committee voted in favour of both forms. The vote is advice: it does not place MOTS-c on the 503A bulks list, which needs FDA to accept it and complete rulemaking. [17]
- US, HHS: not approved (as of 2026-11-02). HHS's enforcement discretion policy, noticed in the Federal Register on 30 October 2026, says HHS does not intend to act against a state-licensed pharmacy, federal facility or licensed physician compounding MOTS-c acetate, for subcutaneous or intramuscular injectable dosage forms, when ten listed conditions are met, among them a patient-specific prescription and a single active ingredient. It does not approve the substance or add it to the 503A bulks list, and it runs until a final rule addresses the substance. The Federal Register notice calls it a draft, takes comments for two weeks after publication and says it is not binding. HHS records that CDER, FDA's drug centre, recommended against listing. Its safety reasoning rests on a trial of a MOTS-c analogue, which it does not name, and on rodent studies; FDA's briefing identified no clinical study of MOTS-c given to people. The policy makes no finding that the substance works. [18]
- US, FDA: not approved (as of 2026-07-23). FDA's briefing document for the July 2026 advisory committee concludes that "a balancing of the criteria weighs against MOTS-c free base or MOTS-c acetate being placed on that list" and proposes "not adding" them. It finds "a lack of evidence to evaluate the effectiveness" for the nominated uses, with the relevant studies "limited to in-vitro and in-vivo rodent models", states that FDA "did not identify clinical studies evaluating administration of MOTS-c-related BDSs in human subjects", and reports FAERS searches through 9 March 2025 that "retrieved no reports". It states that neither form "is a component of an FDA-approved drug". It adds that compounders "generally do not report adverse events to FDA", and that FDA "will not issue a final determination" until the advisory committee process is complete. Read from the full briefing (pp. 1, 7, 28, 31 to 34). [19]
- international, WADA: banned in sport (as of 2026-10-11). Named in WADA's Prohibited List under S4.4.1, metabolic modulators, among "Activators of the AMP-activated protein kinase (AMPK)": "mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)". Section S4 is prohibited at all times, and S4.4 substances are non-Specified. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients; the pasted text does not state the list's year. FDA's July 2026 briefing separately reports MOTS-c as listed in the 2024 list. [20]
- US, FDA: unclear (as of 2026-04-22). FDA's compounding page does not state an approval status for MOTS-c. It states that FDA "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration". No approved product containing MOTS-c was found in the documents read for this page. [15]

## Context

No result from any human trial of MOTS-c was found. One trial of MOTS-c itself is registered: a phase 2a, placebo-controlled study in 120 adults with prediabetes and overweight or obesity, listed as recruiting, with no results ([source](https://clinicaltrials.gov/study/NCT07505745)). A related molecule, CB4211, completed an early trial in 2021 with no results posted and no peer-reviewed publication found ([source](https://clinicaltrials.gov/study/NCT03998514)). The human studies that exist measure the MOTS-c the body makes, and only find associations, in conflicting directions ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC11331736/)). Even the blood test is in doubt: mass spectrometry has not confirmed the levels those studies report ([source](https://doi.org/10.1002/rcm.8337)). No study was found that showed a statistically significant extension of lifespan. That is why this page classes it as preclinical only.

## What it is

MOTS-c, short for "mitochondrial open reading frame of the 12S rRNA-c", is a 16-amino-acid peptide encoded inside the mitochondrial gene MT-RNR1 ([source](https://rest.uniprot.org/uniprotkb/A0A0C5B5G6.txt)). Mitochondria are the energy-producing structures in cells, and they carry their own small genome. The human sequence is MRWQEMGYIFYPRKLR, and FDA's substance registry lists it with no modifications ([source](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A5CV6JFB78)). Its formula is C101H152N28O22S2 and its molecular weight 2174.6 ([source](https://pubchem.ncbi.nlm.nih.gov/compound/146675088)). The discovery paper describes the sequence as highly conserved, so rodent MOTS-c is close to, but not identical with, the human peptide ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/)).

Three things share the name. The body's own MOTS-c is what the blood studies measure. Synthetic "MOTs-c", the spelling FDA uses, is the product nominated for compounding. N-acetyl MOTS-c is a modified version, a different molecule, and nothing on this page is about it.

## Human evidence

> **Key point.**
> No published human study has tested whether taking MOTS-c does anything. The trial designed to test insulin sensitivity in people has not reported ([source](https://clinicaltrials.gov/study/NCT07505745)).

The only human data on an administered peptide concern CB4211, which its developer, CohBar, called "a novel and improved analog of MOTS-c". In a press release filed with the SEC on 10 August 2021, the company reported that CB4211 "appeared safe" in a four-week study of 20 obese adults with fatty liver disease, with injection-site reactions as the most common adverse event, and that both the CB4211 and placebo groups had "substantial reductions in liver fat" ([source](https://www.sec.gov/Archives/edgar/data/1522602/000121390021041377/ea145151ex99-2_cohbar.htm)). This is the company's own announcement, never peer reviewed, about a different molecule whose structure was not found in any source. It says nothing about MOTS-c sold online.

The observational studies point in different directions. A 2024 meta-analysis found plasma MOTS-c lower in diabetes but higher in obesity ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC11331736/)). In one study of 20 adults, higher MOTS-c went with more insulin resistance in lean people ([source](https://doi.org/10.1136/jim-2017-000681)). In men, plasma levels were lower with age while muscle levels were higher ([source](https://doi.org/10.18632/aging.102944)).

> **Limitation.**
> A mass spectrometry method built for doping control could not confirm ELISA-measured plasma levels in 20 healthy people ([source](https://doi.org/10.1002/rcm.8337)), and a 2024 correction by other researchers, withdrawing their own earlier citation of it as proof, states that endogenous MOTS-c "still remains undetected" by that method ([source](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2024.1386502/full)). Every blood-level finding on this page carries that doubt.

## Exercise

MOTS-c is often sold as "exercise in a bottle". The human data run the other way: in 10 sedentary young men, one bout of exercise raised muscle MOTS-c 11.9-fold ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/)), and a randomised exercise study, with the same senior author among its authors, saw only a non-significant trend ([source](https://doi.org/10.1152/japplphysiol.00706.2019)). No human study has tested whether taking MOTS-c reproduces any effect of exercise.

## Animal evidence

> **Evidence.**
> In the discovery paper, MOTS-c improved insulin sensitivity in male mice and prevented obesity on a high-fat diet ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/)). An independent group in Xi'an reported less obesity, insulin resistance and bone loss in ovariectomised mice ([source](https://doi.org/10.1007/s00109-018-01738-w), [source](https://doi.org/10.1016/j.bbrc.2016.05.135)). In male C57BL/6N mice treated from 23.5 months, the originating group reported better physical performance and a lifespan trend that was not significant over the whole survival curve (P = 0.23) ([source](https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/)).

> **Limitation.**
> The discovery paper states that "P.C. is a stockholder of and consultant for, and C.L. is a consultant for CohBar, Inc.", and the late-life mouse study that "P.C. and C.L. are consultants and shareholders of CohBar, Inc.", the company that developed CB4211. Pinchas Cohen is also an author of most of the human studies on this page, including the plasma and muscle studies in Auckland and at the Mayo Clinic, the Japanese cohort study and the randomised exercise study; their own interest statements were not read.

## Regulatory position

FDA lists MOTs-C among bulk substances nominated for compounding and then withdrawn, and states it has identified no human exposure data on products containing it ([source](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)). FDA's briefing explains that "The nomination was withdrawn, and FDA is evaluating the substances at its discretion" (p. 7) ([source](https://www.fda.gov/media/193347/download)).

It was reviewed by FDA's Pharmacy Compounding Advisory Committee on 23 July 2026, with obesity and osteoporosis as the uses listed on the meeting page. FDA's briefing for that meeting, which is not a final determination, found "a lack of evidence to evaluate the effectiveness" for the nominated uses, with the relevant studies "limited to in-vitro and in-vivo rodent models", identified no clinical study of MOTS-c given to people, and weighed against adding it to the 503A compounding list ([source](https://www.fda.gov/media/193347/download)). Press and legal reports, which are second hand, say the committee then voted to recommend MOTS-c for the list, 7 to 5 with two abstentions in one account; FDA had posted no vote record by 6 November 2026, and a recommendation does not put it on the list ([source](https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding), [source](https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know)). In sport, WADA's Prohibited List names MOTS-c under S4.4.1, metabolic modulators, prohibited at all times; the list was read in a browser by a person ([source](https://www.wada-ama.org/en/prohibited-list)). In October 2026 HHS, FDA's parent department, said it does not intend to act against compounders of MOTS-c acetate who meet ten listed conditions ([source](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)). The notice calls that policy a non-binding draft ([source](https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf)); it is not an approval and it does not add MOTS-c to the list.

> **Caution.**
> FDA states that compounded MOTs-C "may pose significant risk for immunogenicity", meaning immune reactions, for certain routes of administration, and that it lacks information on "whether it would cause harm if administered to humans" ([source](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)).

## Sources

1. Zhou Q et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome. 2024. https://doi.org/10.1186/s13098-024-01405-w
2. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry. 2019. https://doi.org/10.1002/rcm.8337
3. Emser SV et al. Corrigendum: Extension of mitogenome enrichment based on single long-range PCR: mtDNAs and putative mitochondrial-derived peptides of five rodent hibernators. Frontiers in Genetics. 2024. https://doi.org/10.3389/fgene.2024.1386502
4. Cataldo LR, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine. 2018. https://doi.org/10.1136/jim-2017-000681
5. Sequeira IR, Merry TL. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochimica et Biophysica Acta General Subjects. 2021. https://doi.org/10.1016/j.bbagen.2021.129991
6. D'Souza RF, Merry TL. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020. https://doi.org/10.18632/aging.102944
7. Qin Q, Lerman A. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. International Journal of Cardiology. 2018. https://doi.org/10.1016/j.ijcard.2017.12.001
8. Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021. https://doi.org/10.18632/aging.202529
9. von Walden F, Alkner B. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology. 2021. https://doi.org/10.1152/japplphysiol.00706.2019
10. Reynolds JC, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. https://doi.org/10.1038/s41467-020-20790-0
11. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. https://doi.org/10.1016/j.cmet.2015.02.009
12. Lu H et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine. 2019. https://doi.org/10.1007/s00109-018-01738-w
13. Ming W et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications. 2016. https://doi.org/10.1016/j.bbrc.2016.05.135
14. Kong BS et al. Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Reports. 2021. https://doi.org/10.1016/j.celrep.2021.109447
15. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
16. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
17. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
18. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
19. FDA Briefing Document for MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. https://www.fda.gov/media/193347/download
20. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. https://www.wada-ama.org/en/prohibited-list
